arrow
D

David Cunningham

University of London
H指数:153
被引数:13.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The role of DNA mismatch repair status in oesophagogastric cancer treated with perioperative chemotherapy: evidence from the MRC ST03 and OE05 trials

DNA错配修复状态在围手术期化疗治疗的食管胃癌中的角色:来自MRC ST03和OE05试验的证据

2026-08-250
OA
Validation of tumour-negative lymph node size as a novel independent prognostic biomarker in oesophagogastric adenocarcinoma: post hoc analysis of the UK MRC OE05 and ST03 randomised trials

肿瘤阴性淋巴结大小作为食管胃腺癌的新型独立预后生物标志物的验证:英国MRC OE05和ST03随机试验的事后分析

2026-08-010
OAAI
The clinical relevance of regional lymph node microarchitecture in oesophageal cancer patients – Results from the UK MRC OE02 trial

食管癌患者区域淋巴结微结构的临床相关性——来自英国MRC OE02试验的结果

2026-06-290
OAAI
Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma—UK Tertiary Cancer Centre Experience

对于 borderline 可切除和局部晚期胰腺腺癌的术前新辅助治疗——英国三级癌症中心的经验

Cancers
IF4.4
2026-05-160
OA
Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial

晚期食管胃腺癌一线铂类化疗后卡培他滨维持治疗:PLATFORM试验的最终分析

2026-04-210
OAAI
Correction: Impact of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel delivery on postoperative survival in locally advanced oesophagogastric adenocarcinoma

更正:围手术期氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛给药对局部晚期食管胃腺癌术后生存的影响

2025-12-190
OAAI
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma

纳武利尤单抗联合 Brentuximab Vedotin 治疗复发/难治性弥漫性大B细胞淋巴瘤

2025-12-100
OAAI
Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial

KRASG12C突变化疗难治性转移性结直肠癌患者接受Sotorasib联合帕尼单抗或标准治疗(CodeBreaK 300):一项III期随机临床试验的结果

2025-08-110
OAAI
The role of PET/CT in peripheral T-cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO-T trial

PET/CT在外周T细胞淋巴瘤中的作用:来自英国NCRI第2阶段CHEMO-T试验PET/CT亚组研究的结果

2025-05-260
PRE
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

Epcoritamab治疗复发/难治性大b细胞淋巴瘤: 关键的EPCORE NHL-1试验的2年随访

LEUKEMIA
IF13.4
2024-09-250
OAAI
Maintenance capecitabine plus ramucirumab after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma (OGA): Final analysis from the PLATFORM trial

在晚期食道胃腺癌(OGA)中,在一线铂类为基础的化疗后进行卡培他滨联合雷莫芦单抗的维持治疗:PLATFORM试验的最终分析

2024-09-011
PRE
Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction: A Network Meta-Analysis

术前放化疗与化疗治疗食管胃结合部腺癌的网状Meta分析

2024-08-021
OAAI
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy Post Hoc Analysis of the SCOT Randomized Clinical Trial

从结直肠癌手术到辅助化疗的时间SCOT随机临床试验的事后分析

2024-08-011
PRE
Maintenance durvalumab after fi rst-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study
2024-07-010
OAAI